FDA advisory committee changes
This article was originally published in The Tan Sheet
FDA releases a 1draft guidance on changes to advisory committee processes, according to a notice slated for publication in the Nov. 19 Federal Register. Among changes, advisory committee members would vote simultaneously rather than sequentially on issues before the panel to avoid influencing one another's votes, the agency says. Although FDA does not mandate any particular voting method, it suggests voting by show of hands, a simultaneous show of "yes" or "no" cards or written balloting. Changes are part of ongoing reforms to the agency's advisory committee policies based on recommendations from the Institute of Medicine and pressure from Congress. In March, FDA issued a draft guidance limiting the potentially conflicting financial interests of members (2"The Tan Sheet" March 26, 2007, p. 7)...
You may also be interested in...
FDA's use of "simultaneous voting" at advisory committee meetings concerning OTC issues in December allowed members to vote free of influence by other members' votes while also proceeding with few technical problems
FDA's policy of granting waivers for financial conflicts of interest for advisory committee members is supported by an independent review commissioned by the agency, which determined that constructing advisory committees free from conflicts of interest would be expensive and time-consuming and may be unfeasible for certain topics and fields of expertise
A "significant fraction" of current FDA advisory committee members' eligibility to vote and participate in meetings would be affected by a revised conflict of interest policy, FDA said